

Review article

Drug-induced liver injury: Diagnosis, management and the role of liver transplantation

Running title: Drug-Induced Liver Injury

N. Begum Ozturk¹, 0000-0002-8595-1838
Eren Uskudar², 0009-0006-4146-1876
Merih Deniz Toruner³, 0000-0001-7447-8654
Cem Simsek², 0000-0002-7037-5233
Ahmet Gurakar², 0000-0002-2221-9148

¹ Department of Internal Medicine, Beaumont Hospital, Royal Oak, Michigan, USA

² Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

³ Brown University Warren Alpert School of Medicine School, Providence, Rhode Island, USA

*Dr. Ozturk and Dr. Uskudar contributed equally to this work.

Corresponding Author

Ahmet Gurakar MD
Medical Director, Liver Transplant
Gastroenterology and Hepatology, Johns Hopkins University School of Medicine
720 Rutland Avenue, Ross Research Building, Suite 918,
Baltimore, MD 21205 USA
Phone: 443 287 0985
Fax: 443 683 8349
Email: aguraka1@jhmi.edu

Abbreviations

ALF: Acute Liver Failure
APAP: Acetaminophen
DILI: Drug-induced liver injury
DILIN: Drug-Induced Liver Injury Network
HDS: Herbal and dietary supplements
LT: Liver transplantation
NAC: N-acetylcysteine
OPTN: Organ Procurement and Transplantation Network
UNOS: United Network for Organ Sharing
US: United States of America

Abstract

Drug-induced liver injury (DILI) is caused by various medications or herbals/nutritional supplements resulting in liver test abnormalities or hepatic dysfunction. DILI can be categorized as direct (intrinsic), idiosyncratic, or immune-mediated (indirect), and patterns of injury can be categorized as hepatocellular, cholestatic, or mixed injury. DILI is diagnosed after excluding other causes of liver injury. Cessation of suspected drug along with supportive care is recommended for the most DILI cases. In life-threatening situations, liver transplantation (LT) can be considered, however the risks with LT and lifelong immunosuppression should be considered. In this paper, we summarize the pathophysiology, diagnosis, medical management, and LT for DILI.

Keywords: Liver injury, toxic hepatitis, liver failure

Introduction

Drug-induced liver injury (DILI) refers to liver damage caused by various medications, or herbals/dietary supplements (HDS), resulting in liver tests abnormalities or hepatic dysfunction, after excluding other possible causes of liver injury. DILI accounts for approximately for 10-15 % of the cases of acute liver failure (ALF), and presents a major challenge for drug safety and development (1). DILI can be classified into three groups including direct (intrinsic), idiosyncratic,

and immune-mediated (indirect) (2–4). Direct hepatotoxicity is common, largely dose-dependent, predictable, and rapid in latency. Direct hepatotoxins such as acetaminophen (APAP) can lead to liver injury after a certain threshold dose in nearly all individuals (2). Idiosyncratic hepatotoxicity is rare, largely dose-independent, unpredictable, and has variable latency (2). Immune-mediated DILI is related to the pharmacodynamic properties of the drug rather than direct or idiosyncratic liver injury, is not dose-related, but partially predictable and arises when the host immune system leads to liver injury following medication administration (3,5).

Mechanisms of drug-induced liver injury

Molecular mechanisms involved in DILI include mitochondrial dysfunction, increased reactive oxygen species generation, depletion of ATP, increased apoptosis and necrosis, altered bile acid homeostasis/bile duct injuries, and as a result cell death by apoptosis or necrosis (Figure 1) (6–8). Patterns of liver injury can be categorized as hepatocellular, cholestatic, or mixed depending on the R-ratio. R-ratio can be calculated with the formulation $(\text{alanine aminotransferase (ALT) / upper limit of normal (ULN) for ALT}) / (\text{alkaline phosphatase (ALP) / ULN for ALP})$. If R-ratio is ≥ 5 the liver injury is classified as hepatocellular, if ≤ 2 cholestatic, and if 2-5 mixed. Hepatocellular or cytolytic injury is characterized by significant elevations in serum aminotransferase levels, which are typically followed by elevated total bilirubin levels and minor elevation in ALP levels. Typical agents causing hepatocellular injury include those caused by valproic acid, isoniazid, or nitrofurantoin (4). Cholestatic liver injury is characterized by elevated ALP levels that precede or are more prominent than elevations in ALT or aspartate aminotransferase (AST), and is associated with drugs such as amoxicillin-clavulanic acid or chlorpromazine. An allergic or immune system reaction is often delayed or seen after repeated exposure to a medication, and may be accompanied by fever, rash, or eosinophilia. This type of liver injury can worsen with repeated exposure to the agent, and is often related to phenytoin, nitrofurantoin, or halothane, referred to as a drug hypersensitivity syndrome. Lastly, mitochondrial injury with microvesicular steatosis on liver biopsy, lactic acidosis, and minor elevations of aminotransferase levels could be induced by medications such as valproic acid or high-dose parenteral tetracycline. Other

medications/herbals/nutrients including aspirin, amiodarone, chemotherapeutic agents, paraquat, carbon tetrachloride, and mushroom poisons can also lead to DILI (9). Several risk factors including age, gender, genetics factors have been suggested for DILI, however no definite risk factor for all-cause DILI exists (10).

Acetaminophen hepatotoxicity

APAP overdose is the most common cause of ALF in the USA and Western Europe (11). APAP causes liver injury predictably and in a dose-related manner, typically with doses exceeding 4 g/day at a single time point or with the excessive doses over several days/weeks. APAP hepatotoxicity can be seen at lower doses in patients who are malnourished or those with alcohol-use disorder. APAP overdose can be seen with intentional or unintentional attempts. In cases of APAP overdose, patients may initially be asymptomatic but can rapidly progress to liver failure within 3-4 days (11).

APAP hepatotoxicity often present with very high transaminase levels, relatively low bilirubin levels, and elevated INR. Serum APAP level after a single-time-point acute ingestion can aid to identify patients with the highest risk of developing liver injury, and the use of modified Rumack-Matthew nomogram is recommended in patients with single-point APAP ingestion to guide N-acetylcysteine (NAC) therapy (2). Early medical intervention is crucial for suspected APAP overdose and hepatotoxicity. Gastric lavage and activated charcoal can be given to patients presenting within 4 hours of ingestion of a single-time-point of APAP ingestion, and oral or IV NAC given within 12 hours of ingestion starting with a loading dose followed by the maintenance dose. NAC is the only effective antidote for severe hepatic necrosis due to APAP overdose. NAC is also recommended if patients present later than 12 hours of ingestion. With the advances in intensive care, especially in the past 2 decades, the outcomes of the patients with APAP hepatotoxicity have improved. However, if patients progress to ALF, approximately one third of the patients require LT or die (2).

Idiosyncratic DILI

Idiosyncratic DILI is rare and reported to occur in 1 to 1,000-1,000,000 people (2). It is characterized by variable drug latency, clinical presentation, and liver histopathology findings, and is thought to be due to aberrant host immune response to the drugs (2). Most commonly implicated medications for idiosyncratic DILI are antimicrobials, immunomodulatory agents, and central nervous system agents (2,10,12,13). HDS constitute the majority of the idiosyncratic DILI in many Asian countries including China and Korea, meanwhile they are responsible for the minority of DILI cases in the United States (US) (2,10,14). HDS account for approximately 20% of all liver injury cases in the US based on Drug-Induced Liver Injury Network (DILIN) Registry data (15). Although idiosyncratic DILI often has a good prognosis, rates of transplant-free survival at 3 weeks in people who develop ALF are 23.5%-38.7% (16). Amoxicillin-clavulanate is the most common medication to be implicated with idiosyncratic DILI in the US and the Western countries, while anti-tuberculosis medications are the most commonly implicated medications in Asia, along with HDS (17). Approximately 80% of the patients with idiosyncratic DILI have resolution without long-term sequelae, and 10% of patients with idiosyncratic DILI are at risk of severe adverse hepatic outcomes including ALF and need for LT (2). Patients with ALF due to idiosyncratic DILI have a 25% chance of spontaneous survival without LT, and early transfer to a LT center is critical for these patients (11).

Causality assessment tools

Several clinical models have been developed to assess the likelihood that a drug or HDS is the cause of liver injury (2). Structural causality assessment models include Roussel-Uclaf Causality Assessment Method (RUCAM), The Maria-Victorino Clinical Diagnostic Scale, Digestive-Disease Week-Japan 2004 (DDW-J) score, and the Revised Electronic Causality Assessment Method (RECAM) (18). Generic causality assessment models include World Health Organization Collaborating Center for International Drug Monitoring system by the Uppsala Monitoring Center. However, there is a lack of consensus in the literature regarding which method of causality assessment is superior. Despite these tools, most cases of DILI are diagnosed by

excluding other causes of liver injury and by considering the temporal relationship of liver injury and initiation of the suspected drug (8).

Medical management of non-acetaminophen DILI

Supportive medical care with analgesia, antiemetics, and parenteral hydration is recommended for all patients with DILI. In patients with ALF due to non-acetaminophen DILI, a 3-day course of NAC can be considered, as a large randomized controlled trial reported improved transplant-free survival, especially in patients with early-stage hepatic encephalopathy (19). Another trial including 102 patients with DILI due to antituberculosis medications reported a shorter length of stay, but no survival benefit with NAC (20). Ursodeoxycholic acid may improve pruritus and DILI recovery, but large randomized controlled trials are lacking for the optimal dose and duration (21). Corticosteroid therapy may be effective in cases with hypersensitivity or autoimmune features.

Role of corticosteroids

Methylprednisolone 1 mg/kg is often used in patients with severe immune-mediated hypersensitivity reactions, and for those with drug reaction with eosinophilia and systemic symptoms. In patients with autoimmune features on liver biopsy, DILI due to immune checkpoint inhibitors or tyrosine kinase inhibitors, a 1–3-month course of corticosteroids with rapid taper may be beneficial, and the dose depends on the severity of hepatitis (22). Data on corticosteroid use in DILI is scarce with no randomized controlled studies to evaluate their efficacy and safety, however, there are reports of corticosteroids having beneficial effects in patients with moderate or severe DILI (18,23). In addition, patients with drug-induced autoimmune hepatitis have good response to corticosteroids (23). Despite this, the majority of patients with DILI recover spontaneously without treatment as reported in several studies. Due to lack of large randomized clinical trials, there is no clear evidence-based recommendation for the indication, dose and duration of treatment (23).

Outcomes

The majority of patients with DILI recover without lasting complications after stopping the suspected medication and supportive care, however ALF or chronic liver injury ranging from asymptomatic liver tests elevations, to vanishing bile duct syndrome and cirrhosis can also be seen with DILI (Figure 2) (24).

Role of liver transplantation

Overall a 10% mortality rate is reported for DILI (25–27). Hospitalized patients with DILI with coagulopathy and hepatic encephalopathy should promptly be considered for LT evaluation as their likelihood of spontaneous recovery is <30% (26,28). A prospective study investigating the fatalities of patients with DILI reported that 7.6% of patients died mainly or partially due to DILI within 2 years, and 40% of the patients had non-ALF courses (26). Patients with chronic DILI, bile duct loss with progression to vanishing bile duct syndrome or progressive portal hypertension may also be considered for LT (28,29). In a study from the European Liver Transplantation Registry over 20 years, out of all LTs performed for ALF, 18% was due to DILI (30). In an observational retrospective study from China conducted between 2012-2014, out of 25,927 patients, 280 (1.08%) patients developed ALF, and of those with ALF, 2 patients (0.01%) underwent LT and 102 (0.30%) died (10). In this study, ALF was defined as INR ≥ 2 , the presence of HE, total bilirubin ≥ 10 times upper limit of normal or daily elevations ≥ 1 mg/dL, and the disease duration of <26 weeks, and DILI was the main reason for death in 52 (70.59%) of the patients. The US Acute Liver Failure Study Group (ALFSG) analyzed 386 patients who were hospitalized with acute liver injury due to DILI showed a 3-week transplant-free survival rate of 87% (31). In contrast, patients with elevated INR and hepatic encephalopathy had higher mortality (32). In the US, idiosyncratic DILI constitutes approximately 13% of all ALF cases, with a 3-week transplant free survival rate of 27% (33). Emergency LT offers significant survival benefit of 3-week survival of 88% following LT (34). In the US, select patients with ALF are priority in the LT waitlist and given Status 1A priority if the life expectancy is <7 days without LT and no preexisting liver disease is present (35,36).

In countries with limited access to deceased-donor LT, living-donor LT can be considered for patients with ALF (35). Apart from patients with DILI requiring LT, DILI after LT is also important to recognize as it is underrecognized in the setting of potential graft rejection or infection (37,38).

Conclusions

Clinical characteristics and presentation of DILI is variable, and a lack of a specific diagnostic tool presents a major challenge for the diagnosis and management. With a reported 10% mortality rate for DILI, LT is reserved as a last-resort option in life-threatening situations, underscoring the gravity of extensive and irreversible liver damage leading to ALF or chronic disease. LT is typically reserved for circumstances with life-threatening complications and when additional medical interventions are unsuccessful. The decision for LT is made on a case-by-case basis, taking into consideration of the patient's overall clinical status, severity of liver damage, and probability of LT-free recovery.

Figure 1.




Figure 2.




Figure 1 Legend: Pathogenesis of DILI.

Figure 2 Legend: Types of DILI and schematic of the outcomes.

References

- Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. *Therap Adv Gastroenterol.* 2023 Mar 21;16:17562848231163410.
- Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. *Hepatology.* 2023 Mar 1;77(3):1036–65.

3. Björnsson H, Björnsson E. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. *European Journal of Internal Medicine*. 2022 Mar 1;97:26–31.
4. Hoofnagle JH, Björnsson ES. Drug-Induced Liver Injury — Types and Phenotypes. *New England Journal of Medicine*. 2019 Jul 18;381(3):264–73.
5. Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, et al. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. *Int J Mol Sci*. 2021 Apr 27;22(9):4557.
6. Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug induced liver injury - a 2023 update. *J Toxicol Environ Health B Crit Rev*. 2023 Nov 17;26(8):442–67.
7. Ye H, Nelson LJ, Moral MG del, Martínez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. *World Journal of Gastroenterology*. 2018 Apr 4;24(13):1373.
8. Iorga A, Dara L, Kaplowitz N. Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis. *International Journal of Molecular Sciences*. 2017 May;18(5):1018.
9. McGill MR, Jaeschke H. Animal models of drug-induced liver injury. *Biochim Biophys Acta Mol Basis Dis*. 2019 May 1;1865(5):1031–9.
10. Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. *Gastroenterology*. 2019 Jun;156(8):2230-2241.e11.
11. Ozturk NB, Herdan E, Saner FH, Gurakar A. A Comprehensive Review of the Diagnosis and Management of Acute Liver Failure. *J Clin Med*. 2023 Nov 30;12(23):7451.
12. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. *Am J Gastroenterol*. 2010 Nov;105(11):2396–404.
13. Edwards D, Lin C, Lin J, Oshima K, King EA, Wesson RN, et al. Delayed onset drug-induced acute liver failure associated with Glatiramer acetate use in multiple sclerosis requiring liver transplantation. *Journal of Liver Transplantation*. 2024 Jan 18;100201.
14. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006. *Hepatol Res*. 2009 May;39(5):427–31.
15. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. *Hepatology*. 2014 Oct;60(4):1399–408.

16. Rao A, Rule JA, Hameed B, Ganger D, Fontana RJ, Lee WM. Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry. *Am J Gastroenterol*. 2022 Apr 1;117(4):617–26.
17. Ahmad J, Odin JA. Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity. *Clin Liver Dis*. 2017 Feb;21(1):55–72.
18. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR, on behalf of the Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. *Am J Gastroenterol*. 2021 May;116(5):878–98.
19. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver Failure. *Gastroenterology*. 2009 Sep 1;137(3):856-864.e1.
20. Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M, et al. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. *Clin Infect Dis*. 2021 Nov 2;73(9):e3377–83.
21. Lang SM, Ortmann J, Rostig S, Schiffh H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. *Int J Mycobacteriol*. 2019;8(1):89–92.
22. Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. *J Dig Dis*. 2016 Sep;17(9):618–27.
23. Björnsson ES, Vucic V, Stirnimann G, Robles-Díaz M. Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. *Front Pharmacol*. 2022;13:820724.
24. Hayashi PH, Björnsson ES. Long-Term Outcomes After Drug-Induced Liver Injury. *Curr Hepatol Rep*. 2018 Sep;17(3):292–9.
25. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. *Gastroenterology*. 2005 Aug 1;129(2):512–21.
26. Hayashi PH, Rockey DC, Fontana RJ, Tillmann HL, Kaplowitz N, Barnhart HX, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. *Hepatology*. 2017 Oct;66(4):1275–85.
27. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. *Gastroenterology*. 2015 Jun;148(7):1340-1352.e7.

28. Fontana RJ, Bjornsson ES, Reddy R, Andrade RJ. The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. *Clin Gastroenterol Hepatol*. 2023 Jul;21(8):2088–99.
29. Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. *Hepatology*. 2017 Apr;65(4):1267.
30. Germani G, Theocharidou E, Adam R, Karam V, Wendon J, O’Grady J, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. *J Hepatol*. 2012 Aug;57(2):288–96.
31. Koch DG, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, et al. The Natural History of Severe Acute Liver Injury. *Am J Gastroenterol*. 2017 Sep;112(9):1389–96.
32. Bernal W, Wendon J. Acute Liver Failure. *New England Journal of Medicine*. 2013 Dec 26;369(26):2525–34.
33. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SHB, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med*. 2002 Dec 17;137(12):947–54.
34. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. *Hepatology*. 2010 Dec;52(6):2065–76.
35. Liou IW, Larson AM. Role of liver transplantation in acute liver failure. *Semin Liver Dis*. 2008 May;28(2):201–9.
36. Pan JJ, Fontana RJ. CAQ Corner: Acute liver failure management and liver transplantation. *Liver Transpl*. 2022 Oct;28(10):1664–73.
37. Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, et al. Frequency, Clinical Presentation, and Outcomes of Drug-Induced Liver Injury after Liver Transplantation. *Liver Transpl*. 2012 Jul;18(7):803–10.
38. Jiménez-Pérez M, González-Grande R, García-Cortés M, Andrade RJ. Drug-Induced Liver Injury After Liver Transplantation. *Liver Transpl*. 2020 Sep;26(9):1167–76.